AI assistant
Sending…
Ocugen, Inc. — Director's Dealing 2018
Aug 1, 2018
32915_dirs_2018-08-01_7acba635-5446-4065-811d-28d817f58102.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: HISTOGENICS CORP (HSGX)
CIK: 0001372299
Period of Report: 2018-07-31
Reporting Person: Kelley Lynne E (Chief Medical Officer)
More from Ocugen, Inc.
Regulatory Filings
2026
May 14
Regulatory Filings
2026
May 14
Regulatory Filings
2026
May 5
Regulatory Filings
2026
May 4
Annual Report
2026
Apr 28
Major Shareholding Notification
2026
Mar 27
Regulatory Filings
2026
Mar 24
Capital/Financing Update
2026
Mar 20
Annual Report
2026
Mar 4
Regulatory Filings
2026
Mar 4